Psychopharmacology in childhood disorders.
Although not explicitly stated elsewhere, it should be clear that medication alone is rarely a sufficient treatment for childhood disorders and should usually be prescribed in conjunction with psychosocial interventions within a biopsychosocial framework. Even when cause is assumed to be largely or wholly biologic, as in infantile autism, there are secondary psychosocial consequences in the child and family that medication does not address. Finally, in the context of careful diagnosis and formulation, the appropriate use of medication is an essential component of effective management.
D000856:Anorexia Nervosa / Q000188:drug therapy; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001010:Anxiety, Separation / Q000188:drug therapy; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D001321:Autistic Disorder / Q000188:drug therapy; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000188:drug therapy; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D004775:Enuresis / Q000188:drug therapy; D006801:Humans; D006963:Hyperphagia / Q000188:drug therapy; D007099:Imipramine / Q000627:therapeutic use; D008094:Lithium / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy; D005879:Tourette Syndrome / Q000188:drug therapy
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D011619:Psychotropic Drugs; D008094:Lithium; D007099:Imipramine